ArticleBio-protocol2026
Step-by-Step Protocol for In Situ Profiling of RNA Subcellular Localization Using TATA-seq.
Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membrane-less organelles play essential roles in both physiological and pathological processes by compartmentalizing biomolecules through phase separation to form dynamic hubs. These hubs enable rapid responses to cellular stress and help maintain cellular homeostasis. However, a straightforward and efficient method for detecting and illustrating the distribution and diversity of RNA species within membrane-less organelles is still highly sought after. In this study, we present a detailed protocol for in situ profiling of RNA subcellular localization using Target Transcript Amplification and Sequencing (TATA-seq). Specifically, TATA-seq employs a primary antibody against a marker protein of the target organelle to recruit a secondary antibody conjugated with streptavidin, which binds an oligonucleotide containing a T7 promoter. This design enables targeted, in situ reverse transcription of RNAs with minimal background noise, a key advantage further refined during data analysis by subtracting signals obtained from a parallel IgG control experiment. The subsequent T7 RNA polymerase-mediated linear amplification ensures high-fidelity RNA amplification from low-input material, which directly contributes to optimized sequencing metrics, including a duplication rate of no more than 25% and a mapping ratio of approximately 90%. Furthermore, the modular design of TATA-seq provides broad compatibility with diverse organelles. While initially developed for membrane-less organelles, the protocol can be readily adapted to profile RNA in other subcellular compartments, such as nuclear speckles and paraspeckles, under both normal and pathogenic conditions, offering a versatile tool for spatial transcriptomics. Key features • This protocol provides subcellular spatial resolution by targeting and sequencing RNA from specific membrane-less organelles. • A T7-based linear amplification step ensures high sensitivity and yield from low-input samples (<10,000 cells). • The method is adaptable for profiling diverse organelles under various biological conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.